Wedbush Initiates Coverage On Cullinan Oncology with Outperform Rating, Announces Price Target of $30
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll initiates coverage on Cullinan Oncology (NASDAQ:CGEM) with an Outperform rating and a price target of $30.

February 15, 2024 | 1:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush has initiated coverage on Cullinan Oncology with an Outperform rating and set a price target of $30.
Analyst ratings, especially from reputable firms like Wedbush, can significantly influence investor sentiment and stock prices. An Outperform rating suggests that the analyst believes CGEM will perform better than the market or its sector, potentially leading to increased investor interest and a rise in stock price. The announcement of a $30 price target further underscores the analyst's bullish outlook on the stock, suggesting a strong upside potential from its current price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100